Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

World Journal of Gastroenterology : WJG
Jonathan StrosbergMichael S Broder

Abstract

To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs) and provide consensus treatment recommendations. Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs, angiogenesis inhibitors, inhibitors of mammalian target of rapamycin and cytotoxic agents. At this time, there is little data to guide treatment selection and sequence. We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations. Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process. After studying the literature, a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale. Ratings were done both before and after an extended discussion of the evidence. Quantitative measurements of agreement were made and consensus statements developed from the second round ratings. Specialties represented were medical and surgical oncology, interventional radiology, and gastroenterology. Panelists had practiced for a mean of 15.5 years (range: 6-33). Among 202 rated ...Continue Reading

References

Jun 25, 1998·The New England Journal of Medicine·P G ShekelleR E Park
May 3, 2000·Alimentary Pharmacology & Therapeutics·P TomassettiL Gullo
Dec 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria A KouvarakiJames C Yao
Jul 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Megan Dann FesinmeyerDeborah J Bowen
Jan 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Jun 3, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T R HalfdanarsonG M Petersen
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew H KulkeMark S Redston
Jul 29, 2010·Pancreas·Aaron I VinikUNKNOWN North American Neuroendocrine Tumor Society (NANETS)
Jul 29, 2010·Pancreas·Matthew H KulkeUNKNOWN North American Neuroendocrine Tumor Society (NANETS)
Jul 29, 2010·Pancreas·Jonathan R StrosbergUNKNOWN North American Neuroendocrine Tumor Society (NANETS)
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Apr 1, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Jonathan R StrosbergLarry K Kvols
Jun 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan R StrosbergLarry K Kvols
Jul 11, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A ChanMatthew H Kulke

❮ Previous
Next ❯

Citations

Oct 21, 2016·Expert Opinion on Pharmacotherapy·Tetsuhide ItoRobert T Jensen
Oct 31, 2015·Chinese Medicine·Pei-Jung ChiangYi-Chang Su
Nov 12, 2015·World Journal of Gastroenterology : WJG·Giuseppe AprileStephen T Sonis
Oct 20, 2018·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Jeffery ChakedisMary Dillhoff
Jan 1, 2015·Rare Cancers and Therapy·Teresa Alonso-GordoaEnrique Grande
Jun 9, 2017·International Journal of Surgical Oncology·Vladimir Neychev, Electron Kebebew
Apr 14, 2017·Journal of Cancer Research and Clinical Oncology·Marco GalloUNKNOWN NIKE Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.